Regeneron Pharmaceuticals (REGN) Q2 2026 Preview: EPS Est. $10.26, Reports July 30

Regeneron Pharmaceuticals (REGN) is projected to report Q2 2026 earnings of $10.26 per share on revenue of $3.82 billion on July 30, before market open. Analyst sentiment has declined, with EPS estimates dropping 5.4% over the past 30 days, reflecting concerns about profitability headwinds. The expected earnings per share represent a significant 20.4% year-over-year decline despite a modest 3.8% revenue growth, suggesting margin compression that will warrant close examination in the upcoming report.